United States Patent 9,758,783 B2: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 9,758,783 B2, titled "Antisense molecules and methods for treating pathologies," is a significant patent in the field of genetic therapies, particularly for treating Duchenne muscular dystrophy (DMD). This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background and Invention Overview
The patent describes antisense molecules designed to bind to specific target sites in the dystrophin gene to induce exon skipping, a process that can mitigate the effects of mutations causing DMD. The invention involves the use of antisense oligonucleotides to modulate the splicing process of pre-mRNA, thereby preventing the synthesis of the undesirable target protein[4].
Scope of the Invention
The scope of the invention is broad and encompasses several key aspects:
Antisense Molecules
The patent details the design and use of antisense oligonucleotides that can bind to selected target sites in the dystrophin gene. These molecules are engineered to promote the decay of targeted mRNA or block its translation, effectively preventing the synthesis of the mutated protein[4].
Exon Skipping
The invention focuses on inducing exon skipping during the splicing process. This is achieved by targeting specific splice sites and motifs within the pre-mRNA, such as donor and acceptor splice sites, exonic splicing enhancers, and silencing elements[4].
Therapeutic Applications
The patent covers the therapeutic use of these antisense molecules for treating genetic diseases, particularly DMD. It outlines methods for administering these molecules to patients and their potential for prophylactic treatment to prevent or minimize the onset of DMD[4].
Claims of the Patent
The claims of the patent are crucial as they define the legal boundaries of the invention.
Claim 1
Claim 1 is a method claim that describes the process of treating a patient with DMD using an antisense molecule designed to induce exon skipping in the dystrophin gene[2].
Subsequent Claims
Subsequent claims further specify the types of antisense molecules, their compositions, and the methods of administration. These claims also cover the use of combinations or "cocktails" of antisense oligonucleotides to enhance exon skipping efficiency[4].
Patent Landscape
Related Patents and Applications
The patent landscape for genetic therapies, especially those involving antisense technology, is complex and evolving. Other patents and applications in this field often focus on similar mechanisms of action, such as exon skipping, but may target different genes or use different types of oligonucleotides.
Global Dossier and International Patent Offices
To understand the global reach of this patent, it is essential to consult resources like the Global Dossier, which provides access to file histories of related applications from participating IP Offices. This helps in identifying similar patents filed in other jurisdictions and understanding the international patent family[1].
Searchable Databases
Utilizing searchable databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO) can help in identifying prior art and similar inventions worldwide[1].
Patent Analytics and Claim Coverage
To fully understand the value and coverage of this patent, patent analytics tools are invaluable. These tools help in categorizing patents by claims and scope concepts, making it easier to identify gaps in coverage and future design opportunities.
Claim Coverage Matrix
A Claim Coverage Matrix can show which patents and claims are actively protecting the intellectual property related to this invention. This matrix helps in identifying where gaps or opportunities exist, allowing for more strategic management of the patent portfolio[3].
Interactive Claim Charts
Interactive claim charts generated by tools like ClaimScape® software can be used to review patent coverage with technical experts. These charts help in determining whether a particular scope concept is applicable to a target product or method, highlighting areas where additional claim coverage may be needed[3].
Legal Status and Expiration
The legal status of the patent is active, but it is crucial to monitor its expiration date and any potential extensions or challenges. The expiration of this patent could open up opportunities for generic entry, as detailed by resources like DrugPatentWatch[5].
Conclusion
United States Patent 9,758,783 B2 is a significant contribution to the field of genetic therapies, particularly for DMD. Understanding its scope, claims, and the broader patent landscape is essential for both the inventors and competitors in this field.
Key Takeaways
- Antisense Molecules: The patent involves the use of antisense oligonucleotides to induce exon skipping in the dystrophin gene.
- Therapeutic Applications: It covers methods for treating DMD and other genetic diseases through exon skipping.
- Claims: The claims define the method of treatment and the composition of the antisense molecules.
- Patent Landscape: The global patent landscape includes similar inventions filed in other jurisdictions, accessible through databases like the Global Dossier.
- Patent Analytics: Tools like Claim Coverage Matrix and interactive claim charts are essential for managing the patent portfolio and identifying gaps in coverage.
FAQs
What is the primary focus of United States Patent 9,758,783 B2?
The primary focus is on the use of antisense molecules to induce exon skipping in the dystrophin gene for treating Duchenne muscular dystrophy (DMD).
How do the antisense molecules work?
The antisense molecules bind to specific target sites in the pre-mRNA to promote the decay of targeted mRNA or block its translation, thereby preventing the synthesis of the mutated protein.
What are the therapeutic applications of this patent?
The patent covers the therapeutic use of these antisense molecules for treating genetic diseases, particularly DMD, and includes methods for prophylactic treatment.
How can one analyze the patent landscape for this invention?
Using resources like the Global Dossier, searchable databases from international patent offices, and patent analytics tools can help in understanding the global reach and related patents.
What is the significance of claim coverage analysis for this patent?
Claim coverage analysis helps in identifying which patents and claims are actively protecting the intellectual property, highlighting gaps in coverage and future design opportunities.
When is the patent set to expire?
The expiration date of the patent needs to be monitored, as it could open up opportunities for generic entry. Resources like DrugPatentWatch provide detailed information on patent expiration and generic entry.
